Clinical Trial Update: Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating trifunctional antibody catumaxomab for recurrent symptomatic malignant ascites has completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites

Drugs mentioned

• Catumaxomab (Catumaxomab)

Snippet

Sponsor: Neovii Biotech | Conditions: Malignant Ascites | Phase 2 | Status: COMPLETED | Results posted: 2012-12-11